Fierce Generic Competition Leads Astellas Into Tier-Based Pricing For Prograf In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Seventeen years after Prograf (tacrolimus) was first introduced into the market, Japan's second largest drug maker, Astellas Pharma, is still counting heavily on its blockbuster transplant drug to push future growth